Thurman, Angela John
McDuffie, Andrea
Hagerman, Randi J.
Josol, Cynde K.
Abbeduto, Leonard
Funding for this research was provided by:
National Institute of Child Health and Human Development (R01 HD054764, U54 HD079125)
Article History
First Online: 10 January 2017
Compliance with Ethical Standards
:
: Authors Angela John Thurman, Andrea McDuffie, and Cynde K. Josol declare that they has no conflict of interest. Author Randi J. Hagerman has received funding from Novartis, Roche Pharmaceuticals, Alcobra and Seaside Therapeutics to carry out treatment studies in fragile X syndrome and ASD. She has also consulted with Roche/Genetech, Zynerba, and Novartis regarding treatment studies in fragile X syndrome. Author Leonard Abbeduto has received financial support to develop and implement outcome measures for clinical trials from F. Hoffman-LaRoche, Ltd., Roche TCRC, Inc. and Neuren Pharmaceuticals Limited.